Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops
Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech revealed plans to lay off 65% of its staff and operate with a skeleton crew to save money.
Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech revealed plans to lay off 65% of its staff and operate with a skeleton crew to save money.
